China Pulmonary Arterial Hypertension Market Size & Outlook
China pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
China pulmonary arterial hypertension market highlights
- The China pulmonary arterial hypertension market generated a revenue of USD 187.8 million in 2023 and is expected to reach USD 302.7 million by 2030.
- The China market is expected to grow at a CAGR of 7.1% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 187.8 million |
| Market revenue in 2030 | USD 302.7 million |
| Growth rate | 7.1% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, China accounted for 2.5% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 191.4 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.5% in 2023. Horizon Databook has segmented the China pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
With high unmet needs, the market is expected to witness profitable growth over the forecast period. Moreover, substantial growth is anticipated due to various healthcare reforms in China. For instance, Life Seeds, the China Rural Health Initiative, is expected to provide improved healthcare access to remote areas of China, creating new avenues for market players.
According to ISEEK Pulmonary Hypertension Hope Center, 2019, more than 5,000 of the China’s 1.4 billion population have been diagnosed with PAH. Complicating the problem is the difficulty in finding appropriate therapies for the disease.
For instance; drug named Tracleer (bosentan), manufactured by the Actelion Pharmaceuticals, retails in China for more than $30,000 per year which is double the annual salary of an average Chinese worker. Furthermore, In China, most of the PAH medications are not covered by the insurance, so the prices are too high to be affordable.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
China Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
